Open-label Study of Bevacizumab (Avastin) and Taxane Monotherapy for the First-line Treatment of Patients With Advanced Triple Negative Breast Cancer

Trial Profile

Open-label Study of Bevacizumab (Avastin) and Taxane Monotherapy for the First-line Treatment of Patients With Advanced Triple Negative Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 31 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Aug 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top